Dr. Lior Shaltiel reports

NUREXONE ANNOUNCES VOTING RESULTS OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS AND PROVIDES CORPORATE UPDATE

Nurexone Biologic Inc. has released the voting results from its annual general and special meeting of the shareholders of the company held on Tuesday, Sept. 15, 2026. Shareholders voted in favour of each resolution put forth at the meeting.

Annual general and special meeting results

Additional information regarding the consolidation is contained in the circular and the company's press release dated Aug. 21, 2026.

At the meeting, there were 33 shareholders represented in person or by proxy holding 32,963,581 shares, representing 34.90 per cent of the issued and outstanding shares as at the record date for the meeting. Each nominee listed in the circular was re-elected as a director of the company, the results of which were as follows.

In addition, at the meeting: (i) shareholders reappointed Ziv Haft CPA (Isr.), a BDO member firm, as the company's auditor for the ensuing year and authorized the audit committee of the board to fix the auditor's remuneration; (ii) disinterested shareholders reapproved the company's amended and restated omnibus equity incentive plan; and (iii) shareholders approved the consolidation resolution, each as more particularly set forth in the circular. The results of such votes were as follows.

Notes

(1) Approved by a majority of the votes cast by disinterested shareholders; 7.58 million shares held by persons ineligible to vote on the plan resolution were excluded from the vote.

(2) The consolidation resolution was approved by not fewer than 66-2/3rds per cent of the votes cast by shareholders at the meeting.

"We appreciate the support provided by shareholders for this enabling step in Nurexone's capital markets strategy," said Yoram Drucker, chairman of the board. "Approval of the consolidation resolution provides the board with flexibility to evaluate market conditions, trading performance and potential U.S. exchange listing requirements before determining whether, when and at what ratio to implement the consolidation."

Shareholder approval authorizes the board, in its sole discretion, to implement a consolidation of up to 30 preconsolidation shares for each one postconsolidation share at any time within 36 months following approval of the consolidation resolution, subject to acceptance of the TSX Venture Exchange and receipt of all other required approvals. Shareholder approval does not require the board to proceed, and the board may revoke the consolidation resolution or elect not to implement the consolidation. Any potential U.S. listing would remain subject to further board approval, acceptance of the TSX-V and the applicable U.S. stock exchange, satisfaction of applicable listing standards, regulatory review, market conditions, and receipt of all other required approvals.

If implemented by the board, the exercise prices and number of shares issuable under the company's outstanding options, restricted share units, warrants and other securities exercisable, settleable or convertible into shares will be proportionately adjusted in accordance with their terms.

Shareholders are not required to take any action at this time. If and when the board determines to implement the consolidation, further details regarding the timing, final ratio and mechanics will be announced in a subsequent news release. No fractional shares will be issued in connection with the consolidation, and any fractional share that would otherwise result from the consolidation will be rounded down to the nearest whole share, as described in the circular.

Investor relations engagement with Acorn Management Partners LLC

The company has entered into a non-exclusive professional relations and capital market consulting agreement with Acorn Management Partners, an arm's-length party based in Alpharetta, Ga. Acorn provides professional relations and capital market services focused on increasing a public company's visibility within the financial professional community. Under the agreement, Acorn will develop and execute a professional relations program designed to communicate the company's publicly disclosed business, financial and corporate developments to licensed brokers, investment professionals and other market participants in the United States. Services may include preparing and distributing educational materials, facilitating discussions and calls with interested financial professionals, providing continuing feedback regarding market and professional interest, and delivering periodic activity reports to the company.

Acorn's approach is focused on professional education and distribution of the company's publicly disclosed investment thesis rather than providing investment recommendations, research ratings or price targets. Acorn's key personnel for the engagement are John Exley III, chief executive officer, and Gregory Lowe, president.

Subject to acceptance by the TSX-V, the agreement has a 12-month term ending Sept. 14, 2027, unless terminated earlier in accordance with its terms. The engagement is a cash-only, fee-for-service arrangement, with Acorn to receive monthly cash compensation with a maximum aggregate base fees of $180,000 (U.S.), plus applicable taxes and approved expenses, payable from the company's working capital. Acorn will not receive any securities of the company as compensation. The company has been advised that neither Acorn nor its key personnel owns or controls any securities of the company, currently intends to acquire any such securities, or participated in a recent financing of the company. Acorn will not commence providing services until TSX-V acceptance has been obtained.

About Nurexone Biologic Inc.

Nurexone is a TSX Venture Exchange-, OTCQB- and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the orphan drug designation, facilitate the company's road map toward clinical trials in the United States and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top to anchor its North American activity and growth strategy.

We seek Safe Harbor.